for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Teva Pharmaceutical Industries Limited

TEVA.TA

Latest Trade

2,756.00ILa

Change

-26.00(-0.93%)

Volume

2,439,822

Today's Range

2,723.00

 - 

2,798.00

52 Week Range

2,175.00

 - 

8,936.00

As of on the Tel Aviv Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
2,782.00
Open
2,770.00
Volume
2,439,822
3M AVG Volume
46.47
Today's High
2,798.00
Today's Low
2,723.00
52 Week High
8,936.00
52 Week Low
2,175.00
Shares Out (MIL)
1,091.00
Market Cap (MIL)
31,494.14
Forward P/E
--
Dividend (Yield %)
--

Next Event

Q3 2019 Teva Pharmaceutical Industries Ltd Earnings Release

Latest Developments

More

Intercure Says Unit Canndoc Entered Strategic Distribution Agreement With Teva Pharmaceuticals Unit

Teva Canada Announces Approval Of Herzuma

Allergan Announces Settlement With Two Ohio Plaintiffs In Federal Opioid Litigation

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams. Its specialty medicines business focuses on delivering a range of solutions to patients and providers through medicines, devices and services in various regions and markets around the world. Its specialty medicines business includes its core therapeutic areas of central nervous system (CNS) and respiratory medicines with a focus on asthma and chronic obstructive pulmonary disease. It also has specialty products in oncology, women's health and selected other areas.

Industry

Biotechnology & Drugs

Contact Info

5 Basel St.,

P.O. Box 3190

+972.3.9267267

http://www.tevapharm.com

Executive Leadership

Sol J. Barer

Independent Chairman of the Board

Kaare Schultz

President, Chief Executive Officer, Director

Michael James McClellan

Chief Financial Officer, Executive Vice President

Iris Beck-Codner

Executive Vice President - Global Brand & Communications

Richard Daniell

Executive Vice President - European Commercial

Key Stats

2.00 mean rating - 1 analysts
Sell
Hold
Buy
Price To Earnings (TTM)
--
Price To Sales (TTM)
0.50
Price To Book (MRQ)
0.63
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
203.40
LT Debt To Equity (MRQ)
183.78
Return on Investment (TTM)
-8.74
Return on Equity (TTM)
-6.58

Latest News

Teva launches generic version of EpiPen for young children

Teva Pharmaceutical Industries Ltd on Tuesday made its generic version of Mylan's EpiPen for young children available in most retail pharmacies at $300 for a 2-pack.

Teva to launch generic version of EpiPen for young children

Teva Pharmaceutical Industries Ltd said on Tuesday its generic version of Mylan's EpiPen for young children will be available in most retail pharmacies at a price of $300 for a 2-pack.

U.S. lawmakers push Mylan, Teva over drug pricing probe

The head of the U.S. House of Representative's oversight panel on Wednesday called on three drugmakers to turn over documents as part of an ongoing congressional review over generic drug price increases and accused the companies of "apparent efforts to stonewall" the probe.

U.S. lawmakers push Mylan, Teva over drug pricing probe -statement

The head of the U.S. House of Representative's oversight panel on Wednesday called on three drugmakers to turn over documents as part of an ongoing congressional review over generic drug price increases and accused the companies of "apparent efforts to stonewall" the probe.

Israel's Teva Pharm profit falls less than expected, CFO to leave

Teva Pharmaceutical Industries <TEVA.TA> reported a smaller-than-expected drop in second-quarter profit on Wednesday and said its chief financial officer was leaving the company.

Israel's Teva Pharm Q2 profit falls less than expected

Israel-based Teva Pharmaceutical Industries reported a smaller-than-expected drop in second-quarter profit on Wednesday and reaffirmed its full year outlook.

Oklahoma judge approves Teva's $85 million opioid settlement

An Oklahoma judge on Monday approved a revised $85 million settlement with Teva Pharmaceutical Industries Ltd resolving claims by the state's attorney general that the drugmaker helped fuel the U.S. opioid epidemic.

Oklahoma judge approves Teva's $85 million opioid settlement

An Oklahoma judge on Monday approved a revised $85 million settlement with Teva Pharmaceutical Industries Ltd resolving claims by the state's attorney general that the drugmaker helped fuel the U.S. opioid epidemic.

Teva Pharm to pay Oklahoma $85 million to settle opioid claims

Teva Pharmaceutical Industries Ltd said on Sunday it had agreed to pay an $85 million settlement with the state of Oklahoma days before the company was set to face trial over allegations that it and other drugmakers helped fuel the U.S. opioid epidemic.

Oklahoma reaches $85 mln settlement with Teva Pharmaceuticals ahead of trial

Oklahoma has reached a $85 million settlement agreement with Israeli-based Teva Pharmaceutical Industries Ltd ahead of the start of a trial in a multibillion-dollar lawsuit over the opioid epidemic, the state's attorney general said on Sunday.

Teva Pharm CFO says company did not conspire to fix prices

Teva Pharmaceutical Industries' chief financial officer on Sunday reiterated that the company has done nothing wrong in the wake of a price-fixing lawsuit filed by 44 U.S. states.

U.S. states accuse Teva, other drugmakers, of price-fixing: lawsuit

U.S. states filed a lawsuit accusing Teva Pharmaceuticals USA Inc of orchestrating a sweeping scheme with 19 other drug companies to inflate drug prices - sometimes by more than 1,000% - and stifle competition for generic drugs, state prosecutors said on Saturday.

U.S. states sue Teva, 19 other drug companies in price-fixing complaint

Forty-four U.S. states have filed a lawsuit accusing 20 drug companies including Teva Pharmaceuticals USA Inc of a sweeping scheme to inflate drug prices and stifle competition for more than 100 generic drugs, state prosecutors said on Saturday.

Teva's new migraine drug helps to contain profit fall

Israel-based Teva Pharmaceutical Industries Ltd on Thursday forecast a sharp rise in revenue next year from its new migraine drug Ajovy and reported a slightly smaller-than-expected drop in first-quarter profit.

Israel's Teva Pharm Q1 profit falls slightly less than forecast

Israel-based Teva Pharmaceutical Industries reported a slightly smaller-than-expected drop in first-quarter profit on Thursday and said it was on track to cut $3 billion of costs by the end of 2019.

Teva stops testing its migraine drug as cluster headache treatment

Teva Pharmaceutical Industries Ltd said on Tuesday it would stop developing its migraine drug, Ajovy, for treating cluster headaches after the company found the treatment was unlikely to meet the main goal of a late-stage trial.

Teva to stop developing cluster headache treatment

Teva Pharmaceutical Industries Ltd said on Tuesday it would stop developing its migraine drug, Ajovy, for treating cluster headaches.

FDA approves Teva's generic nasal spray to treat opioid overdose

Generic drugmaker Teva Pharmaceutical Industries Ltd on Friday received approval from the U.S. Food and Drug Administration (FDA) to market its generic nasal spray for opioid overdose, the health regulator said.

Oklahoma drops several claims in opioid case against J&J, Teva

Oklahoma's attorney general on Thursday had dropped all but a single claim against Johnson & Johnson and Teva Pharmaceutical Industries Ltd in a closely watched lawsuit alleging the drugmakers helped fuel the U.S. opioid epidemic.

Oklahoma drops several claims in opioid case against J&J, Teva

Oklahoma's attorney general on Thursday had dropped all but a single claim against Johnson & Johnson and Teva Pharmaceutical Industries Ltd in a closely watched lawsuit alleging the drugmakers helped fuel the U.S. opioid epidemic.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up